In focus · trending topic

NASH

60 stories · following the connections

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

By Nasdaq OMXFeb 8, 2018, 11:50 AM UTC

Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018

By Nasdaq OMXJan 30, 2018, 12:00 PM UTC

Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs

By Nasdaq OMXJan 25, 2018, 1:31 PM UTC

Immuron to Receive $2.16M R&D Tax Concession Refund

By Nasdaq OMXJan 24, 2018, 2:30 PM UTC

Madrigal Pharmaceuticals Prices Public Offering of Common Stock

By Nasdaq OMXDec 19, 2017, 4:26 AM UTC

Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

By Nasdaq OMXDec 18, 2017, 11:50 AM UTC

Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders

By Nasdaq OMXDec 11, 2017, 2:00 PM UTC

Van Leeuwenhoeck Institute Updates Immuron Research Coverage

By Nasdaq OMXNov 22, 2017, 2:00 PM UTC